The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Links

 

Gene Review

S100a11  -  S100 calcium binding protein A11...

Mus musculus

Synonyms: Calgizzarin, EMAP, EMAPI, Emap1, Endothelial monocyte-activating polypeptide, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of S100a11

  • The heat level of starved Ehrlich ascites carcinoma cells (endogenous) was almost constant and linear and depended on the cell number used in the experiments (about 1 cal/1 X 10(8) cells/hr) [1].
  • Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus [2].
  • Regulation of EMAP II by hypoxia [3].
  • This report investigates the role of neovascularization in the pathogenesis of stromal keratitis by measuring the outcome of treatment with the potent anti-angiogenesis cytokine endothelial monocyte-activating polypeptide II (EMAP II) [4].
  • We show that systemic and topical administration of EMAP II from the outset of infection resulted in markedly diminished levels of herpes simplex virus-induced angiogenesis and significantly reduced the severity of stromal keratitis lesions [4].
 

High impact information on S100a11

  • Endothelial-monocyte activating polypeptide II, a novel antitumor cytokine that suppresses primary and metastatic tumor growth and induces apoptosis in growing endothelial cells [5].
  • Protein QUPC 52 gives maximum binding with isomaltohexaose (IM6) (deltaF degrees = -5,340 cal/mol) and has about 70% of its total binding energy for isomaltotriose (IM3), but at most only 5% for isomaltose (IM2) or methyl alphaDglucoside [6].
  • Endothelial monocyte-activating polypeptide II (EMAP II) is a proinflammatory cytokine and a chemoattractant for monocytes [7].
  • On the other hand, heat evolution was directly related to the amount of glucose added to the medium but not to the number of cells (19 cal/mmol of glucose) [1].
  • The amount of heat produced by the addition of glucose (19 cal/mmol) was equivalent to 40% of the theoretical value of energy released through glycolysis (47 cal/mmol) [1].
 

Chemical compound and disease context of S100a11

  • The effect of the phosphatase inhibitor calyculin A (cal A) on the kinetic parameters of the Na+-coupled taurine uptake via the taurine transporter in the Ehrlich ascites tumour cells has been investigated [8].
 

Biological context of S100a11

 

Anatomical context of S100a11

  • The mature peptide of EMAP alone was capable of inducing the death of cultured endothelial cells, whereas the propeptide was inactive [9].
  • Taken together, our results indicate that calgizzarin expression could be repressed by factors originated from pachytene spermatocytes and/or spermatids [10].
  • In addition, using both RT-PCR analysis and whole-mount in situ hybridization on dissected gonads it was demonstrated that mouse calgizzarin expression starts at 13.5 dpc in the prenatal male gonad and at 16.5 dpc in the embryonic ovary, respectively [10].
  • Calgizzarin is expressed in all adult tissues examined, including testis and ovary; however, a high mRNA level for calgizzarin in mouse testis is maintained until day 15 of postnatal development and then declines dramatically, whereas the expression pattern in the ovary remains constantly high [10].
  • One of the isolated differentially expressed genes, named calgizzarin, belongs to the family of S100 calcium-binding proteins and shows a decreased expression in Sertoli cell-germ cell cocultures compared to cultured Sertoli cells alone [10].
 

Associations of S100a11 with chemical compounds

  • The protein synthesis inhibitor cycloheximide potentiated EMAP-induced apoptosis in endothelial cells [9].
  • Evaluation of the effect of temperature on receptor binding of androgen allowed the estimation of several thermodynamic parameters, including activation energies of association (4 kcal/mol) and dissociation (14 kcal/mol), the apparent free energy (-13 kcal/mol), enthalpy (-9 kcal/mol), and entropy (+14 cal/mol per K) [13].
  • The calorimetric data yielded the following thermodynamic parameters for arachidonic acid: Kd = 4.4 microM, n = 0.8, delta G = -7370 cal/mol, delta H = -6770 cal/mol, and T delta S = +600 cal/mol [14].
  • For oleic acid, the thermodynamic parameters were Kd = 2.4 microM, n = 0.9, delta G = -7770 cal/mol, delta H = -6050 cal/mol, and T delta S = +1720 cal/mol [14].
  • The P67.6 carbohydrate conjugate of calicheamicin is selectively cytotoxic at <0.006 ng/mL of calicheamicin equivalents (cal equiv) toward HL-60 promyelocytic leukemia cells in tissue culture [15].
 

Other interactions of S100a11

 

Analytical, diagnostic and therapeutic context of S100a11

  • Doses of gem-ozo as low as 50 microg cal/kg given three times to mice bearing HL-60 xenografts routinely resulted in long-term, tumor-free survivors, while a nonbinding control conjugate was relatively inactive [18].
  • In a murine allograft model of lung neovascularization and morphogenesis, embryonic lungs transplanted under the skin of immunocompromised mice receiving intraperitoneal EMAP II, had a 56% reduction in vessel density (P<0.0001) compared to control [19].
  • Furthermore, through the use of in situ hybridization and immunohistochemistry, EMAP II is localized throughout the lung, with significant expression in the submyoepithelial area during the early stages of lung development when there is minimal vascular development [20].
  • To unravel neurobiological mechanisms underlying normal anxiety as well as its pathologi- cal variations, animal models are indispensable tools [21].

References

  1. Effects of 2,4-dinitrophenol and other metabolic inhibitors on the thermograms of Ehrlich ascites carcinoma cells registered with a microcalorimeter. Ito, E., Sakihama, H., Toyama, K., Matsui, K. Cancer Res. (1984) [Pubmed]
  2. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus. Gnant, M.F., Berger, A.C., Huang, J., Puhlmann, M., Wu, P.C., Merino, M.J., Bartlett, D.L., Alexander, H.R., Libutti, S.K. Cancer Res. (1999) [Pubmed]
  3. Regulation of EMAP II by hypoxia. Matschurat, S., Knies, U.E., Person, V., Fink, L., Stoelcker, B., Ebenebe, C., Behrensdorf, H.A., Schaper, J., Clauss, M. Am. J. Pathol. (2003) [Pubmed]
  4. Control of stromal keratitis by inhibition of neovascularization. Zheng, M., Schwarz, M.A., Lee, S., Kumaraguru, U., Rouse, B.T. Am. J. Pathol. (2001) [Pubmed]
  5. Endothelial-monocyte activating polypeptide II, a novel antitumor cytokine that suppresses primary and metastatic tumor growth and induces apoptosis in growing endothelial cells. Schwarz, M.A., Kandel, J., Brett, J., Li, J., Hayward, J., Schwarz, R.E., Chappey, O., Wautier, J.L., Chabot, J., Lo Gerfo, P., Stern, D. J. Exp. Med. (1999) [Pubmed]
  6. Binding properties of immunoglobulin combining sites specific for terminal or nonterminal antigenic determinants in dextran. Cisar, J., Kabat, E.A., Dorner, M.M., Liao, J. J. Exp. Med. (1975) [Pubmed]
  7. Regulation of endothelial monocyte-activating polypeptide II release by apoptosis. Knies, U.E., Behrensdorf, H.A., Mitchell, C.A., Deutsch, U., Risau, W., Drexler, H.C., Clauss, M. Proc. Natl. Acad. Sci. U.S.A. (1998) [Pubmed]
  8. Calyculin A modulates the kinetic constants for the Na+-coupled taurine transport in Ehrlich ascites tumour cells. Mollerup, J., Lambert, I.H. Biochim. Biophys. Acta (1998) [Pubmed]
  9. Apoptosis induced by a corneal-endothelium-derived cytokine. Liu, S.H., Gottsch, J.D. Invest. Ophthalmol. Vis. Sci. (1999) [Pubmed]
  10. Developmental stage- and germ cell-regulated expression of a calcium-binding protein mRNA in mouse Sertoli cells. Kraszucka, K., Burfeind, P., Nayernia, K., Köhler, M., Schmid, M., Yaylaoglu, M., Engel, W. Mol. Reprod. Dev. (1999) [Pubmed]
  11. Calgizarrin like gene (Cal) deficient mice undergo normal spermatogenesis. Mannan, A.U., Nica, G., Nayernia, K., Mueller, C., Engel, W. Mol. Reprod. Dev. (2003) [Pubmed]
  12. Epithelial-mesenchymal interactions are linked to neovascularization. Schwarz, M.A., Wan, Z., Liu, J., Lee, M.K. Am. J. Respir. Cell Mol. Biol. (2004) [Pubmed]
  13. Binding kinetics and physical properties of androgen receptor in androgen-dependent Shionogi mammary carcinoma 115. Nohno, T. J. Biochem. (1981) [Pubmed]
  14. Adipocyte lipid-binding protein complexed with arachidonic acid. Titration calorimetry and X-ray crystallographic studies. LaLonde, J.M., Levenson, M.A., Roe, J.J., Bernlohr, D.A., Banaszak, L.J. J. Biol. Chem. (1994) [Pubmed]
  15. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Hamann, P.R., Hinman, L.M., Beyer, C.F., Lindh, D., Upeslacis, J., Flowers, D.A., Bernstein, I. Bioconjug. Chem. (2002) [Pubmed]
  16. Profiling proteins from azoxymethane-induced colon tumors at the molecular level by matrix-assisted laser desorption/ionization mass spectrometry. Chaurand, P., DaGue, B.B., Pearsall, R.S., Threadgill, D.W., Caprioli, R.M. Proteomics (2001) [Pubmed]
  17. Upregulation of macrophage migration inhibitory factor and calgizzarin by androgen in TM4 mouse Sertoli cells. Kasumi, H., Komori, S., Sakata, K., Yamamoto, N., Yamasaki, T., Kanemura, Y., Koyama, K. Asian J. Androl. (2006) [Pubmed]
  18. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Hamann, P.R., Hinman, L.M., Hollander, I., Beyer, C.F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H.R., Upeslacis, J., Shochat, D., Mountain, A., Flowers, D.A., Bernstein, I. Bioconjug. Chem. (2002) [Pubmed]
  19. Endothelial monocyte activating polypeptide II inhibits lung neovascularization and airway epithelial morphogenesis. Schwarz, M.A., Zhang, F., Gebb, S., Starnes, V., Warburton, D. Mech. Dev. (2000) [Pubmed]
  20. EMAP II: a modulator of neovascularization in the developing lung. Schwarz, M., Lee, M., Zhang, F., Zhao, J., Jin, Y., Smith, S., Bhuva, J., Stern, D., Warburton, D., Starnes, V. Am. J. Physiol. (1999) [Pubmed]
  21. Animal models of anxiety. Ohl, F. Handbook of experimental pharmacology. (2005) [Pubmed]
 
WikiGenes - Universities